切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (02) : 60 -63. doi: 10.3877/cma.j.issn.2095-3216.2015.02.001

所属专题: 文献

述评

关注贫困人群的慢性肾脏病
谢院生1,(), 魏凯1, 陈香美1   
  1. 1. 100853 北京,解放军总医院肾脏病科、解放军肾脏病研究所、肾脏疾病国家重点实验室、国家慢性肾病临床医学研究中心
  • 出版日期:2015-04-28
  • 通信作者: 谢院生
  • 基金资助:
    国家重大科学研究计划项目(2011CB944004)

Paying more attention to chronic kidney disease in disadvantaged populations

Yuansheng Xie1,(), Kai Wei1, Xiangmei Chen1   

  1. 1. Department of Nephrology, Chinese People′s Liberation Army General Hospital, Chinese People′s Liberation Army Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing 100853, China
  • Published:2015-04-28
  • Corresponding author: Yuansheng Xie
  • About author:
    Corresponding author: Xie Yuansheng, Email:
引用本文:

谢院生, 魏凯, 陈香美. 关注贫困人群的慢性肾脏病[J]. 中华肾病研究电子杂志, 2015, 04(02): 60-63.

Yuansheng Xie, Kai Wei, Xiangmei Chen. Paying more attention to chronic kidney disease in disadvantaged populations[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(02): 60-63.

慢性肾脏病(CKD),由于其患病率高、预后差、医疗费用高,已成为全球性公共卫生问题。贫困人群由于经济状况、生活方式、生活环境和就医条件等方面的原因,肾脏疾病的发生率更高,肾脏替代疗法的应用率更低,预后更差,经济负担更重。因此,应给予贫困人群CKD更多的关注。2015年第十个世界肾脏日的主题是关注贫困人群的CKD,号召全民关注肾脏健康。本文重点阐述贫穷与CKD之间的关系,旨在提高贫困人群CKD的防治水平。

Chronic kidney disease (CKD) has become a global public health problem due to its high prevalence, poor prognosis, and high cost. Due to the poor economic conditions, lifestyles, living environment, medical conditions, and other aspects, disadvantaged populations have a higher incidence of kidney disease, lower application rates of renal replacement therapy, worse prognosis, and heavier economic burden. Therefore, more attention should be given to CKD in disadvantaged populations. The theme of the tenth World Kidney Day 2015 is to pay attention to the CKD in disadvantaged populations, and appeal to everyone to take good care of their kidneys. This paper focuses on the relationship between poverty and CKD, and aims to improve the prevention and treatment for CKD in disadvantaged populations.

[1]
Collins AJ, Couser WG, Dirks JH, et al. World Kidney Day: an idea whose time has come [J]. J Am Soc Nephrol, 2006,17(3): 600-601.
[2]
Levey AS, Andreoli SP, DuBose T, et al. Chronic kidney disease: common, harmful, and treatable-World Kidney Day 2007 [J]. J Am Soc Nephrol, 2007, 18(2): 374-378.
[3]
Garcia-Garcia G, Jha V. World Kidney Day 2015: CKD in disadvantaged populations [J]. Am J Kidney Dis, 2015, 65(3): 394-353.
[4]
Crews DC, Charles RF, Evans MK, et al. Poverty, race, and CKD in a racially and socioeconomically diverse urban population [J]. Am J Kidney Dis, 2010, 55(6): 992-1000.
[5]
Sachs JD. Macroeconomics and health: investing in health for economic development [J]. Rev Panam Salud Publica, 2002, 12(2): 143-144.
[6]
Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients [J]. Kidney Int, 2003, 63(3): 793-808.
[7]
Hsu C-y, Lin F, Vittinghoff E, et al. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States [J]. J Am Soc Nephrol, 2003, 14(11): 2902-2907.
[8]
Norris K, Nissenson AR. Race, gender, and socioeconomic disparities in CKD in the United States [J]. J Am Soc Nephrol, 2008, 19(7): 1261-1270.
[9]
Bruce MA, Beech BM, Crook ED, et al. Association of socioeconomic status and CKD among African Americans: the Jackson Heart Study [J]. Am J Kidney Dis, 2010, 55(6): 1001-1008.
[10]
Volkova N, McClellan W, Klein M, et al. Neighborhood poverty and racial differences in ESRD incidence [J]. J Am Soc Nephrol, 2008, 19(2): 356-364.
[11]
Sabanayagam C, Lim SC, Wong TY, et al. Ethnic disparities in prevalence and impact of risk factors of chronic kidney disease [J]. Nephrol Dial Transplant, 2010, 25(8): 2564-2570.
[12]
McDonald S. Incidence and treatment of ESRD among indigenous peoples of Australasia[J]. Clin Nephrol, 2010, 74(Suppl 1): S28-S31.
[13]
Collins J. Kidney disease in Maori and Pacific people in New Zealand [J]. Clin Nephrol, 2010, 74 (Suppl 1): S61-S65.
[14]
Weil EJ, Nelson RG. Kidney disease among the indigenous peoples of Oceania [J]. Ethn Dis, 2005, 16(2 Suppl 2): 24-30.
[15]
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives [J]. Lancet, 2013, 382(9888): 260-272.
[16]
Almaguer M, Herrera R, Orantes CM. Chronic kidney disease of unknown etiology in agricultural communities [J]. MEDICC Rev, 2014, 16(2): 9-15.
[17]
Obrador GT, García-García G, Villa AR, et al. Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) Mexico and comparison with KEEP US [J]. Kidney Int Suppl, 2010, 77(116): S2-S8.
[18]
Gutierrez-Padilla JA, Mendoza-Garcia M, Plascencia-Perez S, et al. Screening for CKD and cardiovascular disease risk factors using mobile clinics in Jalisco, Mexico [J]. Am J Kidney Dis, 2010, 55(3): 474-484.
[19]
García-García G, Gutiérrez-Padilla AJ, Chávez-Iñiguez J, et al. Identifying undetected cases of chronic kidney disease in Mexico. Targeting high-risk populations [J]. Arch Med Res, 2013, 44(8): 623-627.
[20]
Amato D, Alvarez-Aguilar C, Castañeda-Limones R, et al. Prevalence of chronic kidney disease in an urban Mexican population [J]. Kidney Int, 2005, 68(97): S11-S17.
[21]
Ulasi II, Ijoma CK, Onodugo OD, et al. Towards prevention of chronic kidney disease in Nigeria: a community-based study in Southeast Nigeria [J]. Kidney Int Suppl, 2013, 3(2): 195-201.
[22]
Otieno LS, McLigeyo SO, Luta M. Acute renal failure following the use of herbal remedies [J]. East Afr Med J, 1991, 68(12): 993-998.
[23]
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379(9818): 815-822.
[24]
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959.
[25]
谢院生. 药物所致急性肾衰的防治经验[J]. 中国综合临床,1990, 6(2): 91-93.
[26]
Hoy W, McDonald SP. Albuminuria: marker or target in indigenous populations [J]. Kidney Int Suppl, 2004, 66(92): S25-S31.
[27]
McDonald SP, Maguire GP, Hoy WE. Renal function and cardiovascular risk markers in a remote Australian aboriginal community [J]. Nephrol Dial Transplant, 2003, 18(8): 1555-1561.
[28]
Lackland DT, Bendall HE, Osmond C, et al. Low birth weights contribute to the high rates of early-onset chronic renal failure in the southeastern United States [J]. Arch Int Med, 2000, 160(10): 1472-1476.
[29]
Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood [J]. N Engl J Med, 2004, 350(9): 865-875.
[30]
Hoy WE, Samuel T, Mott SA, et al. Renal biopsy findings among Indigenous Australians: a nationwide review [J]. Kidney Int, 2012, 82(12): 1321-1331.
[31]
Hoy W, Hughson M, Zimanyi M, et al. Distribution of volumes of individual glomeruli in kidneys at autopsy: association with age, nephron number, birth weight and body mass index [J]. Clin Nephrol, 2010, 74(Suppl 1): S105-S112.
[32]
Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end stage kidney disease: a systematic review [J]. Lancet, 2015, Epub ahead of print.
[33]
Barsoum RS. Chronic kidney disease in the developing world [J]. N Engl J Med, 2006, 354(10): 997-999.
[34]
Jha V. Current status of end-stage renal disease care in India and Pakistan [J]. Kidney Int Suppl, 2013, 3(2): 157-160.
[35]
Garcia-Garcia G, Monteon-Ramos JF, Garcia-Bejarano H, et al. Renal replacement therapy among disadvantaged populations in Mexico: a report from the Jalisco Dialysis and Transplant Registry (REDTJAL) [J]. Kidney Int Suppl, 2005, 68(97): S58-S61.
[36]
Caskey FJ. Renal replacement therapy: can we separate the effects of social deprivation and ethnicity [J]? Kidney Int Suppl, 2013, 3(2): 246-249.
[37]
Yeates KE, Cass A, Sequist TD, et al. Indigenous people in Australia, Canada, New Zealand and the United States are less likely to receive renal transplantation [J]. Kidney Int, 2009, 76(6): 659-664.
[38]
Garcia GG, Harden P, Chapman J, et al. The global role of kidney transplantation [J]. Lancet, 2012, 379(9820): e36-e38.
[39]
Nakai S, Iseki K, Itami N, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010) [J]. Ther Apher Dial, 2012, 16(6): 483-521.
[40]
Jha V. Current status of chronic kidney disease care in southeast Asia [J]. Semin Nephrol, 2009, 29(5): 487-496.
[1] 王丽萍, 徐磊, 蒋天安, 强嘉璘. 微血管成像联合Qpack定量分析技术评估慢性肾脏病患者肾皮质区血流灌注的价值[J]. 中华医学超声杂志(电子版), 2023, 20(03): 292-296.
[2] 周川鹏, 杨浩, 魏微阳, 王奇, 黄亚强. 微创与标准通道经皮肾镜治疗肾结石合并肾功能不全的对比研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 470-475.
[3] 金艳盛, 董改琴, 李晓忠. 巨噬细胞在慢性肾脏病患者血管钙化中的作用与机制研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 234-237.
[4] 杨长沅, 凌曦淘, 丘伽美, 段若兰, 李琴, 林玉婕, 秦新东, 侯海晶, 卢富华, 苏国彬. 慢性肾脏病患者衰弱的筛查/评估工具研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 229-233.
[5] 李思佳, 苏晓乐, 王利华. 通过抑制Wnt/β-catenin信号通路延缓肾间质纤维化研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 224-228.
[6] 程庆砾. 新冠病毒感染与肾脏[J]. 中华肾病研究电子杂志, 2023, 12(04): 240-240.
[7] 王诗远, 张爱华. 慢性肾脏病相关认知障碍的发生机制研究进展[J]. 中华肾病研究电子杂志, 2023, 12(03): 163-167.
[8] 石晓璟, 苏晓乐, 王利华. 直接口服抗凝药在慢性肾脏病合并心房颤动患者中的应用[J]. 中华肾病研究电子杂志, 2023, 12(01): 26-31.
[9] 罗珊, 欧三桃. 激活素A在慢性肾脏病血管钙化中的作用机制研究进展[J]. 中华肾病研究电子杂志, 2022, 11(06): 353-356.
[10] 熊琳, 欧三桃. 慢性肾脏病的"骨-血管轴"的交互因子研究进展[J]. 中华肾病研究电子杂志, 2022, 11(06): 342-346.
[11] 孙雪峰. 肾素-血管紧张素-醛固酮系统抑制剂治疗伴有心力衰竭的慢性肾脏病[J]. 中华肾病研究电子杂志, 2022, 11(06): 301-306.
[12] 李欢, 唐钰书, 王璇, 谢席胜. 慢性肾脏病患者肺部感染的诊治进展[J]. 中华肾病研究电子杂志, 2022, 11(05): 285-289.
[13] 乔晞. CKD合并高血压患者的血压管理[J]. 中华肾病研究电子杂志, 2022, 11(04): 240-240.
[14] 易成, 韦伟, 赵宇亮. 急性肾脏病的概念沿革[J]. 中华临床医师杂志(电子版), 2023, 17(08): 906-910.
[15] 李昌艳, 顾芳, 刘娟, 唐明敏. 非布司他治疗慢性肾脏病伴发高尿酸血症的疗效及预后影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(03): 279-284.
阅读次数
全文


摘要